Cervical Dysplasia News and Research

RSS
PPACA program provides $733,438 grant to Inovio

PPACA program provides $733,438 grant to Inovio

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis doses first patient in FDA-approved phase II CIN trial

Advaxis doses first patient in FDA-approved phase II CIN trial

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Ikonisys to showcase oncoFISH cervical test at Eurogin 2010 Cervical Cancer Prevention Conference

Ikonisys to showcase oncoFISH cervical test at Eurogin 2010 Cervical Cancer Prevention Conference

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

First-quarter fiscal 2010 results announced by Helix BioPharma

First-quarter fiscal 2010 results announced by Helix BioPharma

Fiscal 2009 results announced by Helix BioPharma

Fiscal 2009 results announced by Helix BioPharma

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions

Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions

Less invasive approach for the treatment of cervical intraepithelial neoplasia

Less invasive approach for the treatment of cervical intraepithelial neoplasia

International studies show high efficacy for Gardasil

International studies show high efficacy for Gardasil

Takeda acquires rights for drug to treat cervical dysplasia, HPV

Takeda acquires rights for drug to treat cervical dysplasia, HPV

Investigational treatment for cervical dysplasia

Investigational treatment for cervical dysplasia

Cervical cancer control program increases rate of follow-up

Cervical cancer control program increases rate of follow-up

Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden

Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.